Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali

In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization’s standard 28...

Descripción completa

Detalles Bibliográficos
Autores principales: Diarra, Modibo, Coulibaly, Drissa, Tapily, Amadou, Guindo, Boureima, Sanogo, Koualy, Koné, Diakalia, Koné, Youssouf, Koné, Karim, Bathily, Aboudramane, Yattara, Oumar, Thera, Mahamadou A., Dicko, Alassane, Djimdé, Abdoulaye A., Sagara, Issaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838931/
https://www.ncbi.nlm.nih.gov/pubmed/33498803
http://dx.doi.org/10.3390/tropicalmed6010013
Descripción
Sumario:In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization’s standard 28-day treatment method. The primary endpoint was the clinical and parasitological response corrected by a polymerase chain reaction. It was more than 99.9 percent, the proportion of patients with anemia significantly decrease compared to baseline (p < 0.001), and no serious events were recorded. Plasmodium falciparum remains sensitive to artemether-lumefantrine in Mali.

Ejemplares similares